Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
41 hedge funds and large institutions have $6.01M invested in Navidea Biopharmaceuticals Inc. in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 2 closing their positions.
752% more capital invested
Capital invested by funds: $706K → $6.01M (+$5.31M)
600% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 2
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
77% more call options, than puts
Call options by funds: $285K | Put options by funds: $161K
41% more funds holding
Funds holding: 29 → 41 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$476K |
| 2 |
Two Sigma Investments
New York
|
+$167K |
| 3 |
OFG
OTA Financial Group
Purchase,
New York
|
+$125K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$120K |
| 5 |
ACM
Allred Capital Management
Dallas,
Texas
|
+$91.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
FNY Investment Advisers
New York
|
-$180K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$5.84K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$4K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
-$3.1K |
NAVB Hedge Fund Activity: Q2 2020 in Review
41 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2020, worth a combined $6.01M — up 752% from $706K a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new NAVB positions and 2 closed out — a net gain of 12 holders — while 11 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $476K. The largest seller was FNY Investment Advisers, cutting an estimated $180K.
- 41 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2020, up from 29 in Q1 2020.
- Funds reported $6.01M of Navidea Biopharmaceuticals Inc. stock for Q2 2020, up 752% quarter-over-quarter.
- 14 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2020 and 2 closed out, a net change of +12 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q2 2020 was Renaissance Technologies, an estimated $476K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q2 2020 was FNY Investment Advisers, an estimated $180K sold.
Based on aggregated 13F filings for Q2 2020.